Merck KGaA to buy Silence Therapeutics for $1.3 billion in RNA drug deal
FRANKFURT: German drugmaker Merck KGaA said Monday it agreed to acquire London-based Silence Therapeutics in an all-cash deal valued at about $1.3 billion, adding an experimental treatment for a rare blood cancer and a platform for developing RNA-based medicines. Merck…